

FORWARD-LOOKING AND CAUTIONARY STATEMENTS


This Presentation on behalf of KP Tissue Inc. (the "Corporation" or "KPT") does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for any securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever.

The information contained in this Presentation does not purport to be all-inclusive. This Presentation is being supplied to you solely for your information and may not be reproduced, further distributed or published in whole or in part by any other person. Neither this Presentation nor any copy of it may be taken or transmitted into or distributed any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of securities law.

No representation or warranty, express or implied, is made or given by or on behalf of the Company or any of the directors, officers or employees of any such entities as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. In furnishing this Presentation, the Company does not undertake or agree to any obligation to provide the attendees with access to any additional information or to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. The information and opinions contained in this Presentation are provided as at the date of this Presentation. The contents of this Presentation are not to be construed as legal, financial or tax advice. Each person receiving this Presentation should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal, financial or tax advice.

Certain statements in this presentation about KPT's and KPLP's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements or any other future events or developments constitute forward-looking statements. Forward-looking statements in this presentation include, but are not limited to, statements regarding the projected capacity of the TAD Sherbrooke Project and the Sherbrooke Expansion Project, the anticipated benefits of the TAD Sherbrooke Project and the Sherbrooke Expansion Project and the expected dates for commencement of construction and production of the Sherbrooke Expansion Project; KPLP's expansion efforts in U.S. premium private label; and KPLP's future business strategy. The words "may", "will", "would", "should", "could", "expects", "plans", "intends", "trends", "indications", "anticipates", "believes", "estimates", "predicts", "likely" or "potential" or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. The forward-looking statements are based on certain key expectations and assumptions made by KPT or KPLP. Although KPT and KPLP believe that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking statements since no assurance can be given that such expectations and assumptions will prove to be correct. Unless otherwise stated, references in this Presentation to market shares or KPT's market leadership are based on Nielsen dollar market share data and management estimates. Please refer to the Company's MD&A for the complete Forward-looking and cautionary statements.

CORPORATE STRUCTURE





Dino Bianco
Chief Executive Officer



Mark Holbrook
Chief Financial Officer



INVESTMENT HIGHLIGHTS

- No. 1 tissue company in Canada
- Strong customer relationships with a compelling retail proposition
- Focus on innovation through Bonterra and Cashmere and Purex UltraLuxe launches

- Large, multi-faceted manufacturing capabilities
- Growing US platform with premium private label and White CloudTM brand
- Attractive dividend yield
- Seasoned management team with proven record



OUR VISION IS TO BE THE MOST TRUSTED AND BEST LOVED TISSUE COMPANY IN NORTH AMERICA.



Making everyday life more comfortable.



5 UNDERLYING STRATEGIES

Drive Strong Revenue, Profit and Shareholder Value in a Sustainable Manner

1



Consumer As Our Compass

2



Expand Our Business Footprint

3



End-to-End Supply Chain Excellence

4




Deliver Sustainability

5



Winning Team and Culture

KRUGER PRODUCTS BY NUMBERS






	Revenue	Net Loss	Adjusted EBITDA ⁽²⁾
LTM	\$1.6B	(\$30.6M)	\$109.9M




⁽¹⁾ Nielsen Market, Last 52 weeks ended September 10, 2022. Numbers were rounded.

 $^{(2) \,} Non\text{-}GAAP \ measure - see \ MD\&A \ for \ the \ definition \ and \ reconciliation \ of \ the \ most \ comparable \ GAAP \ measure.$

DIVERSIFIED PORTFOLIO








	Bathroom Tissue	Facial Tissue	Paper Towel	Napkin
Branded	✓	✓	✓	✓
Away-From-Home	✓	\checkmark	✓	✓
Private Label	✓	✓	✓	✓

(1) Segment and geographic splits are based on FY 2021




BRAND LEADERSHIP POSITION




PULP INPUT PRICES

Q3 2022 NBSK average prices¹ in CAD increased 5.8%, while BEK average prices¹ increased 9.3% from Q2 2022.

Q3 2022 NBSK average prices¹ in CAD increased 21.3% and BEK average prices¹ increased 25.3% year-over-year. Based on industry forecasts for 2022, NBSK and BEK prices are expected to remain at elevated levels but continue to be volatile.





(CAD/USD averaged 1.31 in Q3 2022, up 4% from Q3 2021)



HIGH INFLATIONARY PRESSURE

Q3 2022 vs. Q3 2021















ALL PRICING ACTIONS IMPLEMENTED FOR 2022

Pricing Actions in 2022

Consumer Canada

Price increases in July and October

Consumer U.S.

Price increases in Jan/Feb., July and October

AFH

 Price increases in January, May and August 10-12%

Average Price Increase in Q3 2022 (YoY)

Cost Management Plans in 2022

- · Reduced capital spending
- Lower working capital

- Increased productivity
- Cut discretionary SG&A spending





FOCUS ON INNOVATION

Bonterra

- Offers consumers a sustainable solution with bundle of unique features:
 - o Plastic-free paper packaging
 - o High quality FSC® certified recycled fiber
 - o Carbon neutral production
 - o Partnerships with 4Ocean and One Tree Planted
 - o Made in Canada
- Bathroom tissue, facial tissue and paper towel products
- Availability began in March 2022

Cashmere and Purex UltraLuxe

- Significant upgrade using new TAD soft technology to grow ultra-premium segment
- Consumer research confirms it's our softest and most luxurious bathroom tissue ever
- Availability began in February 2022







BRAND SUPPORT

- Q3 2022 and Q4 2022 marketing spend dedicated to in-store and shopper marketing initiatives to drive sales and mitigate price increase impact
- Focusing on managing price gaps following price increases
- Continued awareness and trial-building activities behind Cashmere and Purex UltraLuxe, Sponge Towels UltraPRO, Bonterra and White Cloud launches
- Strong share gains for Sponge Towels UltraPRO and Cashmere/Purex UltraLuxe
- 19th Annual Cashmere Collection in market and Q4 launch of 3rd annual Kruger Big Assist with new Shopping Assist incentive to drive sales





AFH SEGMENT

RECOVERY ONGOING IN COMMERCIAL SECTOR

- Volume remained strong in Q3 2022, 12% higher year-over-year
- Growth in U.S. exceeding market
- EBITDA margin is now positive
- Pricing activity undertaken in 2022 is offsetting inflation
- Commercial tissue capacity remains highly utilized in North America





NETWORK MODERNIZATION

TAD Sherbrooke

- Continuing to exceed ramp-up plans
- Phase 2 of AI implementation progressing according to plan

Sherbrooke Expansion

- Increased total investment to ~\$350 million
- Start-up for bathroom tissue line expected in Q1 2023 with hiring and training phase on track
- Start-up for facial line (Q3 2023) and paper machine line (end of 2024)
- Tracking to plan but closely watching supply chain and inflation





MEMPHIS OPERATIONS


Memphis Performance

- Made improvements to TAD operations (less output variability)
- Re-ignition of efforts on OpEx underway using third-party partner
- Optimizing staff numbers and continuing to train at all levels
- Operational recovery benefit expected in early 2023
- Shutting down older production assets in January 2023

New Facial Tissue Line in Memphis


- Rolled out in July and continues to exceed start-up curve
- Adding new product configurations to expand portfolio
- Provides opportunity for future growth in the U.S.

FINANCIAL PERFORMANCE TREND



Revenue

Adjusted EBITDA⁽¹⁾ and Adjusted EBITDA Margin⁽¹⁾



Net Income (Loss)







⁽¹⁾ Non-GAAP measure – see MD&A for the definition and reconciliation of the most comparable GAAP measure

⁽²⁾ Effective January 1, 2019, KPLP adopted IFRS 16 Leases, the new accounting standard covering lease accounting, using the full retrospective approach. Under this approach, Fiscal 2018 has been restated to reflect the adoption of IFRS 16.

Q3 2022 HIGHLIGHTS








BALANCE SHEET

(Million CAD\$, unless otherwise noted)	Q3 2022	Q2 2022
Cash	82.1	100.3
Current Portion of Long-term Debt	34.6	33.8
Long-term Debt	1,095.0	1,039.5
Net Debt	1,047.7	973.0
LTM Adjusted EBITDA ⁽¹⁾	109.9	119.5
Net Debt/LTM Adjusted EBITDA ⁽¹⁾	9.5x	8.1x

- Net debt increased \$74.7 million sequentially primarily due to a significant FX increase on USD debt, use of financed cash and debt for Sherbrooke Expansion Project and TAD Expansion Project, and for other capital spending and working capital
- Leverage increased due to higher level of net debt and lower LTM Adjusted EBITDA



LOWERED CAPEX



- YTD 2022 CAPEX reached \$76.6 million, including \$15.2 million related to TAD Sherbrooke Project and \$30.2 million related to Sherbrooke Expansion Project
- Projected 2022 CAPEX of \$130-\$140 million, including Sherbrooke Expansion Project
- CAPEX forecast reduced by \$30-\$40
 million from previous quarter due to
 reductions in discretionary projects and
 delays caused by supply chain issues on
 strategic projects



SUSTAINABILITY FOCUS

SUSTAINABLE INNOVATION

PILLAR: PRODUCTS EMPOWER

- FIBRE & FORESTS
- PACKAGING
- PRODUCT INNOVATION

PILLAR: PLANET POSITIVE

- CLIMATE CHANGE
- WATER
- WASTE

PILLAR: EMPLOYEE IMPACT

- HEALTH & SAFETY
- DIVERSITY & CULTURE
- TRAINING & DEVELOPMENT

PILLAR: COMMUNITY EMBRACE

- COMMUNITY INVESTMENT
- EMPLOYEE VOLUNTEERING
- COMMUNITY RELATIONS

OUR 2030 TARGETS

To utilize 100%

third-party certified fibres Scopes 1 + 2 GHG emissions by

25%*

To reduce

To reduce water consumption by

50%*

To reduce virgin plastic packaging in branded products by

50%[†]

- Intensity-based from 2009 baseline
- † Intensity-based from 2020 baseline













KEY TAKEAWAYS

- Continuing to deliver strong top-line growth
- Price increases and cost efficiencies mitigated inflationary pressure in third quarter with further improvement in profitability expected in fourth quarter
- Prudently investing in our brands to support price increases and managing price gaps
- Focus on awareness and trial-building activities behind Cashmere and Purex UltraLuxe, Sponge Towels UltraPRO, Bonterra and White Cloud launches
- TAD Sherbrooke facility continuing to exceed ramp-up curve, while Memphis operational recovery benefit expected in early 2023
- Robust Away-from-Home recovery across North America
- Progressively strengthening liquidity and improving leverage ratio
- Developing organizational capability and culture to drive future growth





